A
Ammar Adam
Researcher at AstraZeneca
Publications - 17
Citations - 677
Ammar Adam is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Venetoclax. The author has an hindex of 10, co-authored 15 publications receiving 448 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Adriana E. Tron,Matthew A. Belmonte,Ammar Adam,Brian Aquila,Brian Aquila,Lawrence H. Boise,Elisabetta Chiarparin,Justin Cidado,Kevin J. Embrey,Eric Gangl,Francis D. Gibbons,Gareth P. Gregory,Gareth P. Gregory,David J. Hargreaves,J. Adam Hendricks,Jeffrey W. Johannes,Ricky W. Johnstone,Ricky W. Johnstone,Steven L. Kazmirski,Jason Grant Kettle,Michelle Lamb,Shannon M. Matulis,Ajay K. Nooka,Martin J. Packer,Bo Peng,Philip B. Rawlins,Daniel W. Robbins,Alwin Schuller,Nancy Su,Wenzhan Yang,Qing Ye,Xiaolan Zheng,J. Paul Secrist,Edwin Clark,David Matthew Wilson,Stephen Fawell,Alexander Hird +36 more
TL;DR: AZD5991 is a macrocyclic molecule with high selectivity and affinity for Mcl-1 that exhibits potent anti-tumor effects as single agent and in combination with bortezomib or venetoclax in preclinical models of multiple myeloma and acute myeloid leukemia.
Journal ArticleDOI
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Alwin Schuller,Evan Barry,Rhys D.O. Jones,Ryan E. Henry,Melanie M. Frigault,Garry Beran,David Linsenmayer,Maureen Hattersley,Aaron Smith,Joanne Wilson,Stefano Cairo,Olivier Déas,Delphine Nicolle,Ammar Adam,Michael Zinda,Corinne Reimer,Stephen Fawell,Edwin Clark,Celina M. D'Cruz +18 more
TL;DR: Data presented provide the first report testing therapeutics in preclinical in vivo models of PRCC and support the clinical development of AZD6094 in this indication, and could robustly suppress pMET and the duration of target inhibition was dose related.
Journal ArticleDOI
Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)
Edward J. Hennessy,Ammar Adam,Brian Aquila,Lillian Castriotta,Donald J. Cook,Maureen Hattersley,Alexander Hird,Christopher Huntington,Victor Kamhi,Naomi Laing,Danyang Li,Terry MacIntyre,Charles A. Omer,Vibha Oza,Troy Patterson,Galina Repik,Michael T. Rooney,Jamal Carlos Saeh,Li Sha,Melissa Vasbinder,Haiyun Wang,David Whitston +21 more
TL;DR: A series of dimeric compounds based on the AVPI motif of Smac were designed and prepared as antagonists of the inhibitor of apoptosis proteins (IAPs), leading to the identification of compound 14 (AZD5582), which binds potently to the BIR3 domains of cI AP1, cIAP2, and XIAP.
Journal ArticleDOI
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy.
Claire Patterson,Srividya B. Balachander,Iain Grant,Petar Pop-Damkov,Brian Kelly,William McCoull,Jeremy S. Parker,Michael Giannis,Hill Kathryn Jane,Francis D. Gibbons,Edward J. Hennessy,Paul D. Kemmitt,Alexander R. Harmer,Sonya Gales,Stuart Purbrick,Sean Redmond,Matthew Skinner,Lorraine Graham,J. Paul Secrist,Alwin Schuller,Shenghua Wen,Ammar Adam,Corinne Reimer,Justin Cidado,Martin Wild,Eric Gangl,Stephen Fawell,Jamal Carlos Saeh,Barry R. Davies,David J. Owen,Marianne Ashford +30 more
TL;DR: In this article, a drug-dendrimer conjugate was developed for the dual Bcl-2/Bcl-xL inhibitor AZD0466, where AZD4320 is chemically conjugated to a PEGylated poly-lysine dendrimers.
Journal ArticleDOI
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B. Balachander,Steven Criscione,Kate Byth,Justin Cidado,Ammar Adam,Paula Lewis,Terry MacIntyre,Shenghua Wen,Deborah Lawson,Kathleen A. Burke,Tristan J. Lubinski,Jeffrey W. Tyner,Stephen E. Kurtz,Shannon K. McWeeney,Jeffrey G. Varnes,Diebold R Bruce,Thomas Gero,Stephanos Ioannidis,Edward J. Hennessy,William McCoull,Jamal Carlos Saeh,Areya Tabatabai,Omid Tavana,Nancy Su,Alwin Schuller,Mathew J. Garnett,Patricia Jaaks,Elizabeth A. Coker,Gareth P. Gregory,Andrea Newbold,Ricky W. Johnstone,Eric Gangl,Martin Wild,Michael Zinda,J. Paul Secrist,Barry R. Davies,Stephen Fawell,Francis D. Gibbons +37 more
TL;DR: AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of B cl-2 prosurvival proteins.